Dr Mark Douglas

Senior Lecturer
Medicine, Westmead Clinical School
Westmead Millennium Institute for Medical Research

Telephone +61 2 9845 7705
Fax +61 2 9635 7582

Map

Biographical details

Dr Douglas is an Infectious Diseases Physician and molecular virologist, with a strong research interest in viral hepatitis. After completing a PhD in virology he undertook a NHMRC CJ Martin Postdoctoral Fellowship on hepatitis C virus (HCV) at the prestigious MRC Virology Unit in the UK, working with Dr John McLauchlan. He now heads the Viral Hepatitis Pathogenesis group at Storr Liver Unit, Westmead Millennium Institute, with a broad range of projects ranging from basic molecular pathogenesis to clinical research. He runs a hepatitis clinic at Blacktown Hospital, treating patients with Chronic Hepatitis B and Hepatitis C, and also sees patients at Westmead Hospital with a range of Infectious Diseases.

The overall aim of his research is to improve the health and well being of people with chronic viral infections.

I am an Infectious Diseases Physician and molecular virologist, with a strong research interest in viral hepatitis.I run a research group at the Westmead Millennium Institute studying hepatitis B virus (HBV) and hepatitis C virus (HCV), with a broad range of projects ranging from basic molecular pathogenesis to clinical research.
I run a hepatitis treatment clinic in Western Sydney, treating patents with chronic Hepatitis B and Hepatitis C, as well as a general Infectious Diseases and HIV clinic.
My current research projects include:
1. Interactions between HCV and cellular lipid pathways.
2. Effects of HCV on the innate antiviral response, including cellular interferons.
3. Mechanisms of HCV replication.
4. Antiviral resistance for HBV and HCV.
5. Factors that affect adherence to antiviral treatment, and how to improve this.
6. How to improve treatment access and support for people from socially disadvantaged groups.
My overall aim is to improve the health and wellbeing of people with chronic viral infections.

Research interests

Dr Douglas undertakes basic and translational research on hepatitis B virus (HBV) and hepatitis C virus (HCV) pathogenesis. His research investigates interactions between hepatitis viruses and their host, focusing on metabolic pathways, cell signalling, innate immunity and induction of liver cancer. He uses novel cellular models to study how virus-host interactions affect virus replication, liver inflammation, liver fibrosis and development of liver cancer.

The aims of his research are to develop new treatments to combat viral hepatitis and to improve response to current antiviral therapies.

Current projects

Current research projects include:

1. Interactions between HCV and cellular lipid pathways.
2. Effects of HCV on the innate antiviral response, including cellular interferons.
3. Mechanisms of HCV replication and how to inhibit them.
4. Antiviral resistance for HBV and HCV.
5. Factors that affect adherence to antiviral treatment, and how to improve this.
6. How to improve treatment access and support for people from socially disadvantaged groups.

International links

Indonesia

(Eijkman Institute, Jakarta Hasanuddin University, Makassar, Sulawesi) Professor David Muljono. We are establishing collaborative projects on the pathogenesis of Hepatitis C virus and clinical studies on Hepatitis B virus, under the Tripartite Collaboration established with the University of Sydney through the Sydney Emerging Infections and Biosecurity Institute (SEIB).

United Kingdom

(Glasgow University) Dr Douglas has an ongoing collaboration with Dr Ian Salt, measuring insulin signalling in cellular models of HCV

United Kingdom

(MRC Virology Unit, Glasgow) Dr Douglas worked as a Postdoc here from 2005-2007 and has an ongoing collaboration on hepatitis C and cellular lipids with Dr John McLauchlan

Selected grants

2014

  • Hepatitis B Virus Genomic Variations and Development of Hepatocellular Carcinoma; Khan A, Douglas M; DVC Research/Postdoctoral Research Fellowship Scheme.

2013

  • A pilot study of fenofibrate to improve hepatitis C virus treatment response - Australian Centre for HIV and Hepatitis Virology Research (ACH2); Douglas M, George J; Commonwealth Department of Health and Ageing/Health Surveillance Fund.
  • Staying Strong and Staying On! – A Psychosocial Screening Tool to Improve Uptake of HCV Treatment; Douglas M; Gilead Sciences (Australia)/Fellowship.
  • Characterization of ARL6IP5 in hepatitis C-related liver cancer; Qiao L, Douglas M, George J; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • Developing functional research partnerships and student exchange, focused on relevant infectious diseases with the Eijkman Institute and Hasanuddin University, Indonesia; Yusuf I, Muljono D, Sorrell T, George J, Marais B, Douglas M; DVC International/IPDF Grant.

2011

  • The role of endocannabinoids in chronic hepatitis C; George J, Douglas M; National Health and Medical Research Council (NHMRC)/Project Grants.

2008

  • mechanisms of metabolic complications in chronic hepatitis C virus infection; Douglas M; Millennium Foundation Ltd/Ludwig Engel Memorial Fellowship.

2005

  • The Influence Of Hepatitis C Virus Genotype On Hepatic Lipid Metabolism; Douglas M; National Health and Medical Research Council (NHMRC)/Early Career Fellowships (ECF).

Selected publications

Download citations: PDF RTF Endnote

Books

  • Douglas, M. (2008). Retrograde Cellular Transport of Herpes Simplex Virus: Interactions between Viral and Motor Proteins - a Gene Therapy Vector for Spinal Cord Disease?. Germany: VDM Verlag Dr Muller.

Book Chapters

  • Read, S., Douglas, M. (2012). Hepatitis C Virus Genotypes. In Geoffrey W. McCaughan, John G. McHutchison, Jean-Michel Pawlotsky (Eds.), Advanced Therapy for Hepatitis C, (pp. 12-16). Chichester, United Kingdom: Wiley-Blackwell Publishing.

Journals

  • Douglas, M., Esmaili, S., George, J. (2014). A new role for IKK-α in Hepatitis C virus induced lipogenesis. Hepatology, 59(5), 2046-2049. [More Information]
  • Beard, M., Ffrench, R., Gowans, E., Helbig, K., Eyre, N., Douglas, M., Grebely, J., Ahlenstiel, G., Locarnini, S., George, J., et al (2014). A Summary of the 20(th) International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology, 147(1), e1-e4. [More Information]
  • Sivagnanam, S., van der Poorten, D., Douglas, M. (2014). Hepatic lesions and eosinophilia in an urban dweller. Liver International, 34(4), 643-643. [More Information]
  • O'Connor, K., Parnell, G., Patrick, E., Ahlenstiel, G., Suppiah, V., van der Poorten, D., Read, S., Leung, R., Douglas, M., Yang, J., Stewart, G., Liddle, C., George, J., Booth, D. (2014). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes and Immunity, 15(2), 88-94. [More Information]
  • O'Connor, K., Ahlenstiel, G., Suppiah, V., Schibeci, S., Ong, A., Leung, R., van der Poorten, D., Douglas, M., Weltman, M., Stewart, G., Liddle, C., George, J., Booth, D. (2014). IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. Innate Immunity, 20(6), 598-605. [More Information]
  • Eslam, M., Leung, R., Romero-Gomez, M., Mangia, A., Irving, W., Sheridan, D., Spengler, U., Mollison, L., Cheng, W., Bugianesi, E., Douglas, M., Booth, D., George, J., Ahlenstiel, G., et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Journal of Hepatology, 61(2), 235-241. [More Information]
  • Read, S., Douglas, M. (2014). Virus induced inflammation and cancer development. Cancer Letters, 345(2), 174-181. [More Information]
  • Fahrtash, F., Kariyawasam, V., Gray, T., Byth Wilson, K., George, J., Douglas, M. (2013). Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World Journal of Gastroenterology, 19(5), 721-726. [More Information]
  • Sublette, V., Douglas, M., McCaffery, K., George, J., Nicholson Perry, K. (2013). Psychological, lifestyle and social predictors of hepatitis c treatment response: a systematic review. Liver International, 33(6), 894-903. [More Information]
  • Pattullo, V., Douglas, M., George, J. (2011). Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? Expert Review of Gastroenterology and Hepatology, 5(2), 265-277. [More Information]
  • Nguyena, O., Sheppeard, V., Douglas, M., Tu, E., Rawlinson, W. (2010). Acute hepatitis C infection with evidence of heterosexual transmission. Journal Of Clinical Virology, 49(1), 65-68. [More Information]
  • van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J., Ho, V., Hebbard, L., Douglas, M., George, J. (2010). Hepatitis C Virus Induces the Cannabinoid Receptor 1. PLoS One, 5(9), 1-10. [More Information]
  • Targett-Adams, P., Boulant, S., Douglas, M., McLauchlan, J. (2010). Lipid metabolism and HCV infection. Viruses, 2(5), 1195-1217. [More Information]
  • Douglas, M., George, J. (2009). Molecular mechanisms of insulin resistance in chronic hepatitis C. World Journal of Gastroenterology, 15(35). [More Information]
  • Boulant, S., Douglas, M., Moody, L., Budkowska, A., Targett-Adam, P., McLauchlan, J. (2008). Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic: the international journal of intracellular transport, 9(8), 1268-1282. [More Information]
  • Diefenbach, R., Miranda Saksena, M., Douglas, M., Cunningham, A. (2008). Transport and egress of herpes simplex virus in neurons. Reviews in Medical Virology, 18(1), 35-51. [More Information]
  • Douglas, M., Stephens, D., Burrow, J., Anstey, N., Talbot, K., Currie, B. (2007). Murray Valley encephalitis in an adult traveller complicated by long-term flaccid paralysis: case report and review of the literature. Transactions of the Royal Society of Tropical Medicine and Hygiene, 101(3), 284-288. [More Information]
  • Cunningham, A., Diefenbach, R., Miranda Saksena, M., Bosnjak, L., Kim, M., Jones, C., Douglas, M. (2006). The cycle of human herpes simplex virus infection: virus transport and immune control. The Journal of Infectious Diseases, 194(Supplement 1), S11-S18. [More Information]
  • Vittone, V., Diefenbach, E., Triffett, D., Douglas, M., Cunningham, A., Diefenbach, R. (2005). Determination of interactions between tegument proteins of herpes simplex virus type 1. Journal of Virology, 79(15), 9566-71. [More Information]
  • Swaminathan, A., Gosbell, I., Zwar, N., Douglas, M. (2005). Tungiasis in recently arrived African refugees. Medical Journal of Australia, 183(1), 51. [More Information]
  • Douglas, M., Lum, G., Roy, J., Fisher, D., Anstey, N., Currie, B. (2004). Epidemiology of community-acquired and nosocomial bloodstream infections in tropical Australia: a 12-month prospective study. Tropical Medicine and International Health, 9(7), 795-804. [More Information]
  • Douglas, M., Diefenbach, R., Homa, F., Miranda Saksena, M., Rixon, F., Vittone, V., Byth Wilson, K., Cunningham, A. (2004). Herpes Simplex Virus Type 1 Capsid Protein Vp26 Interacts With Dynein Light Chains Rp3 And Tctex1 And Plays A Role In Retrograde Cellular Transport. Journal of Biological Chemistry, 279(27), 28522-28530.
  • Diefenbach, R., Diefenbach, E., Douglas, M., Cunningham, A. (2004). The Ribosome Receptor, P180, Interacts With Kinesin Heavy Chain, KIF5B. Biochemical and Biophysical Research Communications, 319(3), 987-992. [More Information]
  • Douglas, M., Johnson, R., Cunningham, A. (2004). Tolerability of Treatments for Postherpetic Neuralgia. Drug Safety, 27(15), 1217-33.
  • Douglas, M., Bradbury, R., Kannangara, S., Mitchell, D. (2003). Arthritis as an Unusual Manifestation of Kikuchi-Fujimoto Disease. Rheumatology (Print Edition), 42(8), 1010-1012.
  • Douglas, M., Fisher, D., Lum, G., Roy, J. (2003). Mycoplasma hominis Infection of a Subdural Haematoma in the Peripartum Period. Pathology, 35(5), 452-454.
  • Douglas, M., Walters, J., Currie, B. (2002). Occupational infection with herpes simplex virus type 1 after a needlestick injury. Medical Journal of Australia, 176(5), 240.
  • Diefenbach, R., Diefenbach, E., Douglas, M., Cunningham, A. (2002). The Heavy Chain of Conventional Kinesin Interacts with the SNARE Proteins SNAP25 and SNAP23. Biochemistry, 41(50), 14906-14915.
  • Douglas, M., Mulholland, K., Denyer, V., Gottlieb, T. (2001). Multi-drug resistant Pseudomonas aeruginosa outbreak in a burns unit - an infection control study. Burns, 27(2), 131-135.

2014

  • Douglas, M., Esmaili, S., George, J. (2014). A new role for IKK-α in Hepatitis C virus induced lipogenesis. Hepatology, 59(5), 2046-2049. [More Information]
  • Beard, M., Ffrench, R., Gowans, E., Helbig, K., Eyre, N., Douglas, M., Grebely, J., Ahlenstiel, G., Locarnini, S., George, J., et al (2014). A Summary of the 20(th) International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology, 147(1), e1-e4. [More Information]
  • Sivagnanam, S., van der Poorten, D., Douglas, M. (2014). Hepatic lesions and eosinophilia in an urban dweller. Liver International, 34(4), 643-643. [More Information]
  • O'Connor, K., Parnell, G., Patrick, E., Ahlenstiel, G., Suppiah, V., van der Poorten, D., Read, S., Leung, R., Douglas, M., Yang, J., Stewart, G., Liddle, C., George, J., Booth, D. (2014). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes and Immunity, 15(2), 88-94. [More Information]
  • O'Connor, K., Ahlenstiel, G., Suppiah, V., Schibeci, S., Ong, A., Leung, R., van der Poorten, D., Douglas, M., Weltman, M., Stewart, G., Liddle, C., George, J., Booth, D. (2014). IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. Innate Immunity, 20(6), 598-605. [More Information]
  • Eslam, M., Leung, R., Romero-Gomez, M., Mangia, A., Irving, W., Sheridan, D., Spengler, U., Mollison, L., Cheng, W., Bugianesi, E., Douglas, M., Booth, D., George, J., Ahlenstiel, G., et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Journal of Hepatology, 61(2), 235-241. [More Information]
  • Read, S., Douglas, M. (2014). Virus induced inflammation and cancer development. Cancer Letters, 345(2), 174-181. [More Information]

2013

  • Fahrtash, F., Kariyawasam, V., Gray, T., Byth Wilson, K., George, J., Douglas, M. (2013). Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World Journal of Gastroenterology, 19(5), 721-726. [More Information]
  • Sublette, V., Douglas, M., McCaffery, K., George, J., Nicholson Perry, K. (2013). Psychological, lifestyle and social predictors of hepatitis c treatment response: a systematic review. Liver International, 33(6), 894-903. [More Information]

2012

  • Read, S., Douglas, M. (2012). Hepatitis C Virus Genotypes. In Geoffrey W. McCaughan, John G. McHutchison, Jean-Michel Pawlotsky (Eds.), Advanced Therapy for Hepatitis C, (pp. 12-16). Chichester, United Kingdom: Wiley-Blackwell Publishing.

2011

  • Pattullo, V., Douglas, M., George, J. (2011). Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? Expert Review of Gastroenterology and Hepatology, 5(2), 265-277. [More Information]

2010

  • Nguyena, O., Sheppeard, V., Douglas, M., Tu, E., Rawlinson, W. (2010). Acute hepatitis C infection with evidence of heterosexual transmission. Journal Of Clinical Virology, 49(1), 65-68. [More Information]
  • van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J., Ho, V., Hebbard, L., Douglas, M., George, J. (2010). Hepatitis C Virus Induces the Cannabinoid Receptor 1. PLoS One, 5(9), 1-10. [More Information]
  • Targett-Adams, P., Boulant, S., Douglas, M., McLauchlan, J. (2010). Lipid metabolism and HCV infection. Viruses, 2(5), 1195-1217. [More Information]

2009

  • Douglas, M., George, J. (2009). Molecular mechanisms of insulin resistance in chronic hepatitis C. World Journal of Gastroenterology, 15(35). [More Information]

2008

  • Boulant, S., Douglas, M., Moody, L., Budkowska, A., Targett-Adam, P., McLauchlan, J. (2008). Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic: the international journal of intracellular transport, 9(8), 1268-1282. [More Information]
  • Douglas, M. (2008). Retrograde Cellular Transport of Herpes Simplex Virus: Interactions between Viral and Motor Proteins - a Gene Therapy Vector for Spinal Cord Disease?. Germany: VDM Verlag Dr Muller.
  • Diefenbach, R., Miranda Saksena, M., Douglas, M., Cunningham, A. (2008). Transport and egress of herpes simplex virus in neurons. Reviews in Medical Virology, 18(1), 35-51. [More Information]

2007

  • Douglas, M., Stephens, D., Burrow, J., Anstey, N., Talbot, K., Currie, B. (2007). Murray Valley encephalitis in an adult traveller complicated by long-term flaccid paralysis: case report and review of the literature. Transactions of the Royal Society of Tropical Medicine and Hygiene, 101(3), 284-288. [More Information]

2006

  • Cunningham, A., Diefenbach, R., Miranda Saksena, M., Bosnjak, L., Kim, M., Jones, C., Douglas, M. (2006). The cycle of human herpes simplex virus infection: virus transport and immune control. The Journal of Infectious Diseases, 194(Supplement 1), S11-S18. [More Information]

2005

  • Vittone, V., Diefenbach, E., Triffett, D., Douglas, M., Cunningham, A., Diefenbach, R. (2005). Determination of interactions between tegument proteins of herpes simplex virus type 1. Journal of Virology, 79(15), 9566-71. [More Information]
  • Swaminathan, A., Gosbell, I., Zwar, N., Douglas, M. (2005). Tungiasis in recently arrived African refugees. Medical Journal of Australia, 183(1), 51. [More Information]

2004

  • Douglas, M., Lum, G., Roy, J., Fisher, D., Anstey, N., Currie, B. (2004). Epidemiology of community-acquired and nosocomial bloodstream infections in tropical Australia: a 12-month prospective study. Tropical Medicine and International Health, 9(7), 795-804. [More Information]
  • Douglas, M., Diefenbach, R., Homa, F., Miranda Saksena, M., Rixon, F., Vittone, V., Byth Wilson, K., Cunningham, A. (2004). Herpes Simplex Virus Type 1 Capsid Protein Vp26 Interacts With Dynein Light Chains Rp3 And Tctex1 And Plays A Role In Retrograde Cellular Transport. Journal of Biological Chemistry, 279(27), 28522-28530.
  • Diefenbach, R., Diefenbach, E., Douglas, M., Cunningham, A. (2004). The Ribosome Receptor, P180, Interacts With Kinesin Heavy Chain, KIF5B. Biochemical and Biophysical Research Communications, 319(3), 987-992. [More Information]
  • Douglas, M., Johnson, R., Cunningham, A. (2004). Tolerability of Treatments for Postherpetic Neuralgia. Drug Safety, 27(15), 1217-33.

2003

  • Douglas, M., Bradbury, R., Kannangara, S., Mitchell, D. (2003). Arthritis as an Unusual Manifestation of Kikuchi-Fujimoto Disease. Rheumatology (Print Edition), 42(8), 1010-1012.
  • Douglas, M., Fisher, D., Lum, G., Roy, J. (2003). Mycoplasma hominis Infection of a Subdural Haematoma in the Peripartum Period. Pathology, 35(5), 452-454.

2002

  • Douglas, M., Walters, J., Currie, B. (2002). Occupational infection with herpes simplex virus type 1 after a needlestick injury. Medical Journal of Australia, 176(5), 240.
  • Diefenbach, R., Diefenbach, E., Douglas, M., Cunningham, A. (2002). The Heavy Chain of Conventional Kinesin Interacts with the SNARE Proteins SNAP25 and SNAP23. Biochemistry, 41(50), 14906-14915.

2001

  • Douglas, M., Mulholland, K., Denyer, V., Gottlieb, T. (2001). Multi-drug resistant Pseudomonas aeruginosa outbreak in a burns unit - an infection control study. Burns, 27(2), 131-135.

To update your profile click here. For support on your academic profile contact .